Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
November 29, 2007

ChemGenex Lets Go of Metabolic Diseases Segment

  • ChemGenex Pharmaceuticals is demerging its metabolic diseases business, Autogen Research. The divested segment will be renamed Verva Pharmaceuticals and will merge with Adipogen Pharmaceuticals.

    The merger with Adipogen Pharmaceuticals is expected to be completed by December 20. Adipogen Pharmaceuticals is an early-stage firm developing therapies for obesity.

    Verva Pharmaceuticals will seek to list on the Australian Securities Exchange in the first quarter of next year. ChemGenex will receive one share in Verva Pharmaceuticals for every five it holds at the record date, which is December 12.

    “Through this restructuring, ChemGenex is now well-positioned to devote its resources to the development and commercialization of the anticancer assets in late-stage development, while enabling Verva Pharmaceuticals to focus on the development of novel therapeutics in the field of type 2 diabetes and obesity,” states Greg Collier, Ph.D., CEO and managing director. The company’s lead product is currently in Phase II/III trials for the treatment of chronic myeloid leukemia.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.